Literature DB >> 24914142

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Boglarka Gyurkocza1, Brenda M Sandmaier2.   

Abstract

An essential component of allogeneic and autologous hematopoietic cell transplantation (HCT) is the conditioning regimen administered before the hematopoietic cell infusion. Early regimens relied on dose intensity, assuming that high-dose chemoradiotherapy would eliminate malignant disease and reinfusion of the graft would then restore hematopoiesis. However, as the contribution of graft-versus-tumor effects to the success of allogeneic HCT was recognized over time, in an effort to exploit these, many investigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen. This resulted in a major paradigm shift, and consequently, the pool of eligible patients underwent a remarkable expansion. In this article, we provide a review of the definition of high-dose, reduced-intensity, and nonmyeloablative conditioning regimens, the most commonly used agents and combinations, and the evolution of some early regimens. We also provide a brief review of the toxicities associated with these regimens.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24914142      PMCID: PMC4102707          DOI: 10.1182/blood-2014-02-514778

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  102 in total

1.  Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation.

Authors:  Michael Haidinger; René Geyeregger; Marko Poglitsch; Thomas Weichhart; Maximilian Zeyda; Barbara Vodenik; Thomas M Stulnig; Georg A Böhmig; Walter H Hörl; Marcus D Säemann
Journal:  Transplantation       Date:  2007-07-15       Impact factor: 4.939

2.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

3.  Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Authors:  Betul Oran; Sergio Giralt; Rima Saliba; Chitra Hosing; Uday Popat; Issa Khouri; Daniel Couriel; Muzaffar Qazilbash; Paolo Anderlini; Partow Kebriaei; Shubhra Ghosh; Antonio Carrasco-Yalan; Ernesto de Meis; Athanasios Anagnostopoulos; Michele Donato; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2007-02-08       Impact factor: 5.742

4.  High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

Authors:  Ajay K Gopal; Joseph G Rajendran; Ted A Gooley; John M Pagel; Darrell R Fisher; Stephen H Petersdorf; David G Maloney; Janet F Eary; Frederick R Appelbaum; Oliver W Press
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

5.  Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Authors:  Amrita Krishnan; Auayporn Nademanee; Henry C Fung; Andrew A Raubitschek; Arturo Molina; Dave Yamauchi; Roberto Rodriguez; Ricardo T Spielberger; Peter Falk; Joycelynne M Palmer; Stephen J Forman
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

6.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Christoph Kahl; Barry E Storer; Brenda M Sandmaier; Marco Mielcarek; Michael B Maris; Karl G Blume; Dietger Niederwieser; Thomas R Chauncey; Stephen J Forman; Edward Agura; Jose F Leis; Benedetto Bruno; Amelia Langston; Michael A Pulsipher; Peter A McSweeney; James C Wade; Elliot Epner; Finn Bo Petersen; Wolfgang A Bethge; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

7.  Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Authors:  Asha B Pillai; Tracy I George; Suparna Dutt; Samuel Strober
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

8.  Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.

Authors:  M Iravani; M R Evazi; S A Mousavi; A R Shamshiri; M Tavakoli; A Ashouri; S Samiee; B Chahardovali; K Alimoghaddam; S H Ghaffari; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2007-04-30       Impact factor: 5.483

9.  Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Authors:  Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos de Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

10.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

View more
  125 in total

1.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.

Authors:  A Ruggeri; M Labopin; F Ciceri; M Mohty; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-12-14       Impact factor: 5.483

2.  Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Authors:  Mahmoud Elsawy; Barry E Storer; Filippo Milano; Brenda M Sandmaier; Colleen Delaney; Rachel B Salit; Ahmed H Rashad; Ann E Woolfrey; Frederick R Appelbaum; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation.

Authors:  Ashley Leak Bryant; Erin Coffman; Brett Phillips; Xianming Tan; Elizabeth Bullard; Rachel Hirschey; Joshua Bradley; Antonia V Bennett; Angela M Stover; Lixin Song; Thomas C Shea; William A Wood
Journal:  Support Care Cancer       Date:  2019-06-20       Impact factor: 3.603

Review 4.  Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Pietro Merli; Mattia Algeri; Francesca Del Bufalo; Franco Locatelli
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

Review 5.  Cellular transplant therapies for globoid cell leukodystrophy: Preclinical and clinical observations.

Authors:  Keri R Maher; Andrew M Yeager
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

6.  Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Authors:  J R Passweg; M Labopin; J Cornelissen; L Volin; G Socié; A Huynh; R Tabrizi; D Wu; C Craddock; N Schaap; J Kuball; P Chevallier; J Y Cahn; D Blaise; A Ghavamzadeh; K Bilger; F Ciceri; C Schmid; S Giebel; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

7.  Isolation and Characterization of a Fetal-Maternal Microchimeric Stem Cell Population in Maternal Hair Follicles Long after Parturition.

Authors:  Cosmin Andrei Cismaru; Olga Soritau; Ancuta-Maria Jurj; Raduly Lajos; Bogdan Pop; Cosmina Bocean; Bogdan Albzour; Oana Baldasici; Cristian Moldovan; Ioana Berindan Neagoe
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

8.  In vivo engineering of bone tissues with hematopoietic functions and mixed chimerism.

Authors:  Yu-Ru Shih; Heemin Kang; Vikram Rao; Yu-Jui Chiu; Seong Keun Kwon; Shyni Varghese
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

9.  (211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

Authors:  Christopher R Burtner; Devikha Chandrasekaran; Erlinda B Santos; Brian C Beard; Jennifer E Adair; Donald K Hamlin; D Scott Wilbur; Brenda M Sandmaier; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

10.  Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Authors:  Richard J Lin; Patrick D Hilden; Theresa A Elko; Parastoo B Dahi; Armin Shahrokni; Ann A Jakubowski; Miguel-Angel Perales; Craig S Sauter; Hugo R Castro-Malaspina; Juliet N Barker; Brian C Shaffer; Roni Tamari; Esperanza B Papadopoulos; Molly A Maloy; Beatriz Korc-Grodzicki; Sergio A Giralt
Journal:  Blood Adv       Date:  2019-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.